NASDAQ:ADIL Adial Pharmaceuticals - ADIL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.31 -0.01 (-3.12%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.30▼$0.3450-Day Range$0.20▼$0.3752-Week Range$0.20▼$2.62Volume256,641 shsAverage Volume190,196 shsMarket Capitalization$8.04 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Adial Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside864.6% Upside$3.00 Price TargetShort InterestHealthy0.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 stars 3.3 Analyst's Opinion Consensus RatingAdial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Adial Pharmaceuticals has a forecasted upside of 864.6% from its current price of $0.31.Amount of Analyst CoverageAdial Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.56% of the outstanding shares of Adial Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently increased by 12.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADIL. Previous Next 3.0 News and Social Media Coverage News SentimentAdial Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adial Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest6 people have searched for ADIL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows1 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders23.88% of the stock of Adial Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.42% of the stock of Adial Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($0.51) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adial Pharmaceuticals (NASDAQ:ADIL) StockAdial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.Read More Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Stock News HeadlinesNovember 16, 2022 | seekingalpha.comAdial Pharmaceuticals GAAP EPS of -$0.12 beats by $0.06October 4, 2022 | finance.yahoo.comAdial Pharma Touts Positive Preclinical Data From Chronic Pain CandidateJanuary 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…September 28, 2022 | benzinga.comAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic PainSeptember 26, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainSeptember 26, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainSeptember 22, 2022 | seekingalpha.comADIL Adial Pharmaceuticals, Inc.September 6, 2022 | nasdaq.comAdial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative ColitisJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.September 6, 2022 | finance.yahoo.comAdial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease CandidateSeptember 6, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative ColitisSeptember 1, 2022 | finance.yahoo.comHere's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom FisherAugust 29, 2022 | finance.yahoo.comZacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight EnterprisesAugust 23, 2022 | seekingalpha.comAdial Clinical Trial: A Fluff Or A Win?August 18, 2022 | uk.investing.comAdial Pharmaceuticals Provides Business Update, Reports Q2August 17, 2022 | seekingalpha.comAdial gets cut at Maxim on need for capital to map path for alcohol disorder drugAugust 16, 2022 | finance.yahoo.comAdial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsAugust 16, 2022 | finance.yahoo.comAdial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsJuly 20, 2022 | finance.yahoo.comEXCLUSIVE: Adial Pharma's AD04 Effective In Heavy Drinker Alcohol Use Disorder PatientsJuly 20, 2022 | seekingalpha.comAdial stock slumps 25% as AD04 fails to best placebo in very heavy drinkers in trialJuly 20, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use DisorderJuly 18, 2022 | finance.yahoo.comAdial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use DisorderJune 28, 2022 | finance.yahoo.comAdial Pharmaceuticals Provides Letter to Shareholders From CEO William StilleyJune 27, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical TrialJune 14, 2022 | seekingalpha.comAdial gets US patent linked to AD04, diagnostic test for alcohol/opioid use disorderJune 14, 2022 | finance.yahoo.comAdial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?June 14, 2022 | finance.yahoo.comAdial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug DependenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Company Calendar Last Earnings11/14/2022Today1/29/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+864.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-227.60% Return on Assets-156.55% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio5.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book1.83Miscellaneous Outstanding Shares25,850,000Free Float19,680,000Market Cap$8.04 million OptionableNot Optionable Beta0.60 Key ExecutivesCary J. ClaibornePresident, Chief Executive Officer & DirectorJoseph TruluckChief Financial Officer, Secretary & TreasurerBankole A. JohnsonChief Medical OfficerJulien DimastromatteoVice President-ResearchAlex LugovoyChief Business OfficerKey CompetitorsCoeptis TherapeuticsNASDAQ:COEP180 Life SciencesNASDAQ:ATNFNeptune Wellness SolutionsNASDAQ:NEPTArtelo BiosciencesNASDAQ:ARTLNeuBase TherapeuticsNASDAQ:NBSEView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 243,962 shares on 11/15/2022Ownership: 1.025%Virtu Financial LLCBought 45,681 shares on 11/7/2022Ownership: 0.301%View All Institutional Transactions ADIL Stock - Frequently Asked Questions Should I buy or sell Adial Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares. View ADIL analyst ratings or view top-rated stocks. What is Adial Pharmaceuticals' stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 864.6% from the stock's current price. View analysts price targets for ADIL or view top-rated stocks among Wall Street analysts. How have ADIL shares performed in 2023? Adial Pharmaceuticals' stock was trading at $0.2150 at the beginning of 2023. Since then, ADIL stock has increased by 44.7% and is now trading at $0.3110. View the best growth stocks for 2023 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 144,500 shares, an increase of 12.3% from the December 31st total of 128,700 shares. Based on an average daily trading volume, of 140,900 shares, the short-interest ratio is presently 1.0 days. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its earnings results on Monday, November, 14th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.06. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? (ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. What is Adial Pharmaceuticals' stock symbol? Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL." How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adial Pharmaceuticals' stock price today? One share of ADIL stock can currently be purchased for approximately $0.31. How much money does Adial Pharmaceuticals make? Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $8.04 million. The company earns $-19,420,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. How can I contact Adial Pharmaceuticals? Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com. This page (NASDAQ:ADIL) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.